Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.64 |
| ▸ | IGF1R | P08069 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.64 |
| ▸ | INSR | P06213 | 2/20 | 0.64 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.61 |
| ▸ | EML4 | Q9HC35 | 3/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.59 |
| ▸ | ROS1 | P08922 | 1/20 | 0.59 |
| ▸ | FER | P16591 | 1/20 | 0.59 |
| ▸ | LTK | P29376 | 1/20 | 0.59 |
| ▸ | BLK | P51451 | 1/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19532476 | 0.92 | EGFR (0.61) | EGFRIGF1RKCNH2INSRPTK2 | |
| SCHEMBL19254057 | 0.91 | EGFR (0.56) | EGFRIGF1RKCNH2INSRALK | |
| SCHEMBL17683121 | 0.91 | EGFR (0.63) | EGFRIGF1RKCNH2INSRALK | |
| SCHEMBL17683119 | 0.90 | EGFR (0.62) | EGFRIGF1RKCNH2INSR | |
| SCHEMBL17682981 | 0.89 | EGFR (0.68) | EGFRIGF1RKCNH2INSRALK | |
| SCHEMBL17683218 | 0.88 | EGFR (0.65) | EGFR | |
| SCHEMBL19532475 | 0.87 | EGFR (0.61) | EGFRIGF1RKCNH2INSRPTK2 | |
| SCHEMBL17682936 | 0.86 | EGFR (0.60) | EGFRIGF1RKCNH2INSRALK | |
| SCHEMBL17682986 | 0.86 | EGFR (0.68) | EGFRIGF1RKCNH2INSRALK | |
| SCHEMBL17683110 | 0.85 | EGFR (0.62) | EGFRIGF1RKCNH2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205650-B1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3205650-B1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-10-01 | — | — | US | disclosed |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-10-01 | — | — | US | disclosed |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016054987-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885IGF1R 18/4885KCNH2 4088/4885 |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885IGF1R 50/4885KCNH2 3977/4885 |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885IGF1R 50/4885KCNH2 3977/4885 |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885IGF1R 18/4885KCNH2 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.